|
ATE430565T1
(de)
|
2001-02-28 |
2009-05-15 |
Merck & Co Inc |
Acylierte piperidinderivate als melanocortin-4- rezeptoragonisten
|
|
JP4323169B2
(ja)
*
|
2001-02-28 |
2009-09-02 |
メルク エンド カムパニー インコーポレーテッド |
メラノコルチン−４受容体作働薬としてのアシル化ピペリジン誘導体
|
|
US6911447B2
(en)
|
2001-04-25 |
2005-06-28 |
The Procter & Gamble Company |
Melanocortin receptor ligands
|
|
ATE411021T1
(de)
|
2001-07-18 |
2008-10-15 |
Merck & Co Inc |
Überbrückte piperidinderivate als melanocortin- rezeptor-agonisten
|
|
US6977264B2
(en)
|
2001-07-25 |
2005-12-20 |
Amgen Inc. |
Substituted piperidines and methods of use
|
|
US7115607B2
(en)
|
2001-07-25 |
2006-10-03 |
Amgen Inc. |
Substituted piperazinyl amides and methods of use
|
|
US7354923B2
(en)
|
2001-08-10 |
2008-04-08 |
Palatin Technologies, Inc. |
Piperazine melanocortin-specific compounds
|
|
US7456184B2
(en)
|
2003-05-01 |
2008-11-25 |
Palatin Technologies Inc. |
Melanocortin receptor-specific compounds
|
|
JP3813152B2
(ja)
|
2002-03-12 |
2006-08-23 |
メルク エンド カムパニー インコーポレーテッド |
置換アミド類
|
|
US7026335B2
(en)
|
2002-04-30 |
2006-04-11 |
The Procter & Gamble Co. |
Melanocortin receptor ligands
|
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
|
WO2004024720A1
(en)
|
2002-09-11 |
2004-03-25 |
Merck & Co., Inc. |
Piperazine urea derivatives as melanocortin-4 receptor agonists
|
|
US7132539B2
(en)
|
2002-10-23 |
2006-11-07 |
The Procter & Gamble Company |
Melanocortin receptor ligands
|
|
MY134457A
(en)
*
|
2002-11-22 |
2007-12-31 |
Merck & Co Inc |
Substituted amides
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
WO2004078717A1
(en)
*
|
2003-03-03 |
2004-09-16 |
Merck & Co., Inc. |
Acylated piperazine derivatives as melanocortin-4 receptor agonists
|
|
US6998488B2
(en)
|
2003-03-10 |
2006-02-14 |
Merck & Co., Inc. |
Process and intermediates for the preparation of 4-aryl piperidines
|
|
US7276520B2
(en)
|
2003-03-26 |
2007-10-02 |
Merck & Co., Inc. |
Bicyclic piperidine derivatives as melanocortin-4 receptor agonists
|
|
GB0308333D0
(en)
*
|
2003-04-10 |
2003-05-14 |
Glaxo Group Ltd |
Novel compounds
|
|
AR044510A1
(es)
*
|
2003-04-14 |
2005-09-14 |
Merck & Co Inc |
Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina
|
|
US7049323B2
(en)
|
2003-04-25 |
2006-05-23 |
Bristol-Myers Squibb Company |
Amidoheterocycles as modulators of the melanocortin-4 receptor
|
|
AU2004259717A1
(en)
*
|
2003-07-22 |
2005-02-03 |
Merck & Co., Inc. |
Piperidine derivatives as melanocortin-4 receptor agonists
|
|
CA2551037A1
(en)
|
2003-09-22 |
2005-03-31 |
Banyu Pharmaceutical Co., Ltd. |
Novel piperidine derivative
|
|
US20050192286A1
(en)
*
|
2003-10-22 |
2005-09-01 |
Neurocrine Biosciences, Inc. |
Ligands of melanocortin receptors and compositions and methods related thereto
|
|
US7989634B2
(en)
|
2003-11-12 |
2011-08-02 |
Lg Life Sciences Ltd. |
Melanocortin receptor agonists
|
|
GB0402492D0
(en)
*
|
2004-02-04 |
2004-03-10 |
Pfizer Ltd |
Pharmaceutically active compounds
|
|
US7649002B2
(en)
|
2004-02-04 |
2010-01-19 |
Pfizer Inc |
(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
|
|
CA2560314A1
(en)
|
2004-03-29 |
2005-10-20 |
Merck & Co., Inc. |
Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
|
|
EP2305352A1
(en)
|
2004-04-02 |
2011-04-06 |
Merck Sharp & Dohme Corp. |
5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
|
|
CN1984662A
(zh)
*
|
2004-07-16 |
2007-06-20 |
默克公司 |
用作黑皮质素－4受体激动剂的酰基化哌啶衍生物
|
|
DE602005018779D1
(de)
|
2004-07-19 |
2010-02-25 |
Merck & Co Inc |
Acylierte piperidinderivative als melanocortin-4-rezeptoragonisten
|
|
CA2575736A1
(en)
|
2004-08-06 |
2006-02-16 |
Merck & Co., Inc. |
Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
|
|
US20080085885A1
(en)
*
|
2004-08-13 |
2008-04-10 |
Linda Bristow |
Inhibition Of Voluntary Ethanol Consumption With Non-Peptidyl Melanocortin-4 Receptor Agonists
|
|
US20080021067A1
(en)
*
|
2004-10-05 |
2008-01-24 |
Linda Bristow |
Methods For The Treatment Of Substance Abuse And Addiction
|
|
TW200630337A
(en)
|
2004-10-14 |
2006-09-01 |
Euro Celtique Sa |
Piperidinyl compounds and the use thereof
|
|
WO2006049933A2
(en)
*
|
2004-10-29 |
2006-05-11 |
Merck & Co., Inc. |
Compositions and methods for the treatment of obesity and sexual dysfunction
|
|
BRPI0518241A
(pt)
|
2004-11-01 |
2008-04-22 |
Amylin Pharmaceuticals Inc |
métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
|
|
WO2006057904A1
(en)
*
|
2004-11-23 |
2006-06-01 |
Merck & Co., Inc. |
Stereoselective preparation of 4-aryl piperidine amides by asymmetric hydrogenation of a prochiral enamide and intermediates of this process
|
|
GB0428514D0
(en)
*
|
2004-12-31 |
2005-02-09 |
Prosidion Ltd |
Compounds
|
|
EP1892241B1
(en)
|
2005-05-30 |
2016-03-30 |
Msd K.K. |
Novel piperidine derivative
|
|
US8129413B2
(en)
|
2005-06-27 |
2012-03-06 |
Merck Sharp & Dohme Corp. |
Crystalline forms of MC4R agonist and process for synthesis
|
|
KR20080047375A
(ko)
|
2005-07-29 |
2008-05-28 |
콘서트 파마슈티컬즈, 인크. |
약제 화합물
|
|
CA2617654A1
(en)
*
|
2005-08-04 |
2007-02-08 |
Pfizer Limited |
Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
|
|
JPWO2007018248A1
(ja)
|
2005-08-10 |
2009-02-19 |
萬有製薬株式会社 |
ピリドン化合物
|
|
AU2006279680B2
(en)
|
2005-08-11 |
2012-12-06 |
Amylin Pharmaceuticals, Llc |
Hybrid polypeptides with selectable properties
|
|
EP2330125A3
(en)
|
2005-08-11 |
2012-12-12 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
|
US7875633B2
(en)
|
2005-08-24 |
2011-01-25 |
Banyu Pharmaceutical Co., Ltd. |
Phenylpyridone derivative
|
|
JPWO2007029847A1
(ja)
|
2005-09-07 |
2009-03-19 |
萬有製薬株式会社 |
二環性芳香族置換ピリドン誘導体
|
|
WO2007041052A2
(en)
|
2005-09-29 |
2007-04-12 |
Merck & Co., Inc. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
|
US20100160306A1
(en)
*
|
2005-09-30 |
2010-06-24 |
Bakshi Raman K |
Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists
|
|
WO2007047496A2
(en)
|
2005-10-18 |
2007-04-26 |
Merck & Co., Inc. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
|
US20080255084A1
(en)
|
2005-10-21 |
2008-10-16 |
Randy Lee Webb |
Combination of Organic Compounds
|
|
JPWO2007049798A1
(ja)
|
2005-10-27 |
2009-04-30 |
萬有製薬株式会社 |
新規ベンゾオキサチイン誘導体
|
|
WO2007055418A1
(ja)
|
2005-11-10 |
2007-05-18 |
Banyu Pharmaceutical Co., Ltd. |
アザ置換スピロ誘導体
|
|
EP1801098A1
(en)
|
2005-12-16 |
2007-06-27 |
Merck Sante |
2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
|
|
JP5243274B2
(ja)
*
|
2006-02-23 |
2013-07-24 |
ファイザー・リミテッド |
４型メラノコルチン受容体アゴニストのピペリジノイルピロリジン
|
|
EA200801738A1
(ru)
*
|
2006-02-23 |
2008-12-30 |
Пфайзер Лимитед |
Пиперидиноилпирролидиновые агонисты меланокортинового рецептора 4 типа
|
|
US8247442B2
(en)
|
2006-03-29 |
2012-08-21 |
Purdue Pharma L.P. |
Benzenesulfonamide compounds and their use
|
|
US8791264B2
(en)
|
2006-04-13 |
2014-07-29 |
Purdue Pharma L.P. |
Benzenesulfonamide compounds and their use as blockers of calcium channels
|
|
WO2007118854A1
(en)
|
2006-04-13 |
2007-10-25 |
Euro-Celtique S.A. |
Benzenesulfonamide compounds and the use thereof
|
|
WO2007124045A2
(en)
*
|
2006-04-20 |
2007-11-01 |
Ampla Pharmaceuticals, Inc. |
Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity
|
|
TWI332501B
(en)
*
|
2006-07-14 |
2010-11-01 |
Lg Life Sciences Ltd |
Melanocortin receptor agonists
|
|
EP2062878A4
(en)
*
|
2006-08-30 |
2010-09-08 |
Shionogi & Co |
HYDRAZINE AMIDE DERIVATIVE
|
|
EP2083831B1
(en)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
|
WO2008038692A1
(en)
|
2006-09-28 |
2008-04-03 |
Banyu Pharmaceutical Co., Ltd. |
Diaryl ketimine derivative
|
|
CA2673359A1
(en)
*
|
2006-12-18 |
2008-06-26 |
7Tm Pharma A/S |
Cb1 receptor modulators
|
|
EP1935420A1
(en)
|
2006-12-21 |
2008-06-25 |
Merck Sante |
2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
|
|
JP5319518B2
(ja)
|
2007-04-02 |
2013-10-16 |
Ｍｓｄ株式会社 |
インドールジオン誘導体
|
|
US8399486B2
(en)
*
|
2007-04-09 |
2013-03-19 |
Purdue Pharma L.P. |
Benzenesulfonyl compounds and the use thereof
|
|
DK2170930T3
(da)
|
2007-06-04 |
2012-11-05 |
Synergy Pharmaceuticals Inc |
Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
WO2009040659A2
(en)
|
2007-09-28 |
2009-04-02 |
Purdue Pharma L.P. |
Benzenesulfonamide compounds and the use thereof
|
|
AU2009220605A1
(en)
|
2008-03-06 |
2009-09-11 |
Msd K.K. |
Alkylaminopyridine derivative
|
|
EP2272841A1
(en)
|
2008-03-28 |
2011-01-12 |
Banyu Pharmaceutical Co., Ltd. |
Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
|
|
EP2110374A1
(en)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
|
|
WO2009154132A1
(ja)
|
2008-06-19 |
2009-12-23 |
萬有製薬株式会社 |
スピロジアミン-ジアリールケトオキシム誘導体
|
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
|
JPWO2010013595A1
(ja)
|
2008-07-30 |
2012-01-12 |
Ｍｓｄ株式会社 |
５員−５員又は５員−６員縮環シクロアルキルアミン誘導体
|
|
JP5530438B2
(ja)
|
2008-08-06 |
2014-06-25 |
ファイザー・リミテッド |
Ｍｃ４作動薬としてのジアゼピンおよびジアゾカン化合物
|
|
US8410284B2
(en)
|
2008-10-22 |
2013-04-02 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
|
EP2362731B1
(en)
|
2008-10-31 |
2016-04-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
UA99555C2
(en)
|
2008-11-12 |
2012-08-27 |
Элджи Лайф Саенсез Лтд. |
Melanocortin receptor agonists
|
|
WO2010056717A1
(en)
|
2008-11-17 |
2010-05-20 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic amines for the treatment of diabetes
|
|
WO2010067233A1
(en)
|
2008-12-08 |
2010-06-17 |
Pfizer Inc. |
1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
|
|
JP2012512221A
(ja)
*
|
2008-12-16 |
2012-05-31 |
エフ．ホフマン−ラ ロシュ アーゲー |
ピロリジン−３−カルボン酸の製造方法
|
|
EP2389374A1
(en)
|
2009-01-20 |
2011-11-30 |
Pfizer Inc. |
Substituted pyrazinone amides
|
|
WO2010086820A1
(en)
|
2009-02-02 |
2010-08-05 |
Pfizer Inc. |
4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof
|
|
WO2010089685A1
(en)
|
2009-02-03 |
2010-08-12 |
Pfizer Inc. |
4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives
|
|
EP2393811A1
(en)
|
2009-02-04 |
2011-12-14 |
Pfizer Inc. |
4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives
|
|
US8889674B2
(en)
|
2009-03-05 |
2014-11-18 |
Shionogi & Co., Ltd. |
Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism
|
|
EP2406230A1
(en)
|
2009-03-11 |
2012-01-18 |
Pfizer Inc. |
Substituted indazole amides and their use as glucokinase activators
|
|
UA99882C2
(uk)
|
2009-03-11 |
2012-10-10 |
Пфайзер Інк. |
Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
|
|
WO2010106457A2
(en)
|
2009-03-20 |
2010-09-23 |
Pfizer Inc. |
3-oxa-7-azabicyclo[3.3.1]nonanes
|
|
NZ596467A
(en)
|
2009-06-05 |
2014-01-31 |
Pfizer |
L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
|
|
WO2011011508A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
|
WO2011011506A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
|
EP2480551A1
(en)
|
2009-09-23 |
2012-08-01 |
Pfizer Inc. |
Gpr 119 modulators
|
|
ME02016B
(me)
|
2009-11-02 |
2015-05-20 |
Pfizer |
Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola
|
|
CA2778316A1
(en)
|
2009-11-10 |
2011-05-19 |
Pfizer Inc. |
N-2 pyrazolospiroketone acetyl-coa carboxylase inhibitors
|
|
CA2778886C
(en)
|
2009-11-10 |
2014-01-07 |
Pfizer Inc. |
N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
|
|
JP2013510834A
(ja)
|
2009-11-16 |
2013-03-28 |
メリテク |
［１，５］‐ジアゾシン誘導体
|
|
CA2780463A1
(en)
|
2009-11-23 |
2011-05-26 |
Pfizer Inc. |
Imidazo-pyrazoles as gpr119 inhibitors
|
|
EP2521721B1
(en)
|
2009-12-30 |
2014-10-01 |
Shanghai Fochon Pharmaceutical Co. Ltd |
3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
|
|
US9044606B2
(en)
|
2010-01-22 |
2015-06-02 |
Ethicon Endo-Surgery, Inc. |
Methods and devices for activating brown adipose tissue using electrical energy
|
|
US8476227B2
(en)
|
2010-01-22 |
2013-07-02 |
Ethicon Endo-Surgery, Inc. |
Methods of activating a melanocortin-4 receptor pathway in obese subjects
|
|
JP2013520502A
(ja)
|
2010-02-25 |
2013-06-06 |
メルク・シャープ・エンド・ドーム・コーポレイション |
有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
|
|
HUE025774T2
(en)
|
2010-03-19 |
2016-05-30 |
Pfizer |
2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro[3.6]nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
|
|
US8785634B2
(en)
|
2010-04-26 |
2014-07-22 |
Merck Sharp & Dohme Corp |
Spiropiperidine prolylcarboxypeptidase inhibitors
|
|
US9365539B2
(en)
|
2010-05-11 |
2016-06-14 |
Merck Sharp & Dohme Corp. |
Prolylcarboxypeptidase inhibitors
|
|
WO2011156246A1
(en)
|
2010-06-11 |
2011-12-15 |
Merck Sharp & Dohme Corp. |
Novel prolylcarboxypeptidase inhibitors
|
|
WO2011158149A1
(en)
|
2010-06-18 |
2011-12-22 |
Pfizer Inc. |
2-(3,5-disubstitutedphenyl)pyrimidin-4(3h)-one derivatives
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
PT2621493T
(pt)
|
2010-09-30 |
2016-11-14 |
Pfizer |
Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
|
|
PL2632925T3
(pl)
|
2010-10-29 |
2015-10-30 |
Pfizer |
N1/N2-laktamowe inhibitory karboksylazy acetylo-CoA
|
|
RU2013127611A
(ru)
|
2010-12-23 |
2015-01-27 |
Пфайзер Инк. |
Модуляторы глюкагонового рецептора
|
|
MX2013009140A
(es)
|
2011-02-08 |
2013-10-01 |
Pfizer |
Moduladores del receptor de glucagon.
|
|
SG192941A1
(en)
|
2011-02-25 |
2013-09-30 |
Merck Sharp & Dohme |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
|
EA022375B1
(ru)
|
2011-04-22 |
2015-12-30 |
Пфайзер Инк. |
ПРОИЗВОДНЫЕ ПИРАЗОЛОСПИРОКЕТОНОВ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ
|
|
EP2731944A1
(en)
|
2011-07-15 |
2014-05-21 |
Pfizer Inc |
Gpr 119 modulators
|
|
RU2013157388A
(ru)
|
2011-07-22 |
2015-08-27 |
Пфайзер Инк. |
Хинолинильные модуляторы глюкагонового рецептора
|
|
EA201400990A1
(ru)
|
2012-04-06 |
2015-01-30 |
Пфайзер Инк. |
Ингибиторы диацилглицеринацилтрансферазы 2
|
|
US8889730B2
(en)
|
2012-04-10 |
2014-11-18 |
Pfizer Inc. |
Indole and indazole compounds that activate AMPK
|
|
CA2872154C
(en)
|
2012-05-04 |
2016-08-23 |
Pfizer Inc. |
Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2
|
|
WO2014022528A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
WO2014045162A1
(en)
|
2012-09-20 |
2014-03-27 |
Pfizer Inc. |
ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-ANIME COMPOUNDS
|
|
EP2931731A1
(en)
|
2012-12-11 |
2015-10-21 |
Pfizer Inc. |
Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
|
|
JP6162820B2
(ja)
|
2012-12-19 |
2017-07-12 |
ファイザー・インク |
炭素環式および複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
|
|
WO2014125394A1
(en)
|
2013-02-13 |
2014-08-21 |
Pfizer Inc. |
HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
|
|
US9233981B1
(en)
|
2013-02-15 |
2016-01-12 |
Pfizer Inc. |
Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
|
JP2016516004A
(ja)
|
2013-02-22 |
2016-06-02 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
抗糖尿病二環式化合物
|
|
EP2970119B1
(en)
|
2013-03-14 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
US9486494B2
(en)
|
2013-03-15 |
2016-11-08 |
Synergy Pharmaceuticals, Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
CA2905438A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
JP6606491B2
(ja)
|
2013-06-05 |
2019-11-13 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
EP3055300B1
(en)
|
2013-10-09 |
2018-03-07 |
Pfizer Inc |
Antagonists of prostaglandin ep3 receptor
|
|
TR201809388T4
(tr)
|
2014-03-17 |
2018-07-23 |
Pfizer |
Metabolik ve ilişkili hastalıkların tedavisinde kullanılmaya yönelik diasilgliserol asiltransferaz 2 inhibitörleri.
|
|
AU2015245260A1
(en)
|
2014-04-10 |
2016-10-06 |
Pfizer Inc. |
2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides
|
|
MX386063B
(es)
*
|
2014-05-29 |
2025-03-18 |
Mitsubishi Tanabe Pharma Corp |
Compuesto de pirrolidina novedoso, y aplicación como agonista del receptor de melanocortina.
|
|
BR112017003745A2
(pt)
|
2014-08-29 |
2017-12-05 |
Tes Pharma S R L |
inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
|
|
WO2016092413A1
(en)
|
2014-12-10 |
2016-06-16 |
Pfizer Inc. |
Indole and indazole compounds that activate ampk
|
|
JP2017538769A
(ja)
|
2014-12-22 |
2017-12-28 |
ファイザー・インク |
プロスタグランジンｅｐ３受容体の拮抗薬
|
|
US10080884B2
(en)
|
2014-12-29 |
2018-09-25 |
Ethicon Llc |
Methods and devices for activating brown adipose tissue using electrical energy
|
|
US10092738B2
(en)
|
2014-12-29 |
2018-10-09 |
Ethicon Llc |
Methods and devices for inhibiting nerves when activating brown adipose tissue
|
|
TN2017000485A1
(en)
|
2015-06-17 |
2019-04-12 |
Pfizer |
Tricyclic compounds and their use as phosphodiesterase inhibitors
|
|
JP2018531924A
(ja)
|
2015-09-24 |
2018-11-01 |
ファイザー・インク |
テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
|
|
AU2016325665A1
(en)
|
2015-09-24 |
2018-03-08 |
Pfizer Inc. |
N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
|
|
EP3353174A1
(en)
|
2015-09-24 |
2018-08-01 |
Pfizer Inc |
N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors
|
|
RU2696269C1
(ru)
|
2015-12-29 |
2019-08-01 |
Пфайзер Инк. |
Замещенные 3-азабицикло[3.1.0]гексаны в качестве ингибиторов кетогексокиназы
|
|
AR109179A1
(es)
|
2016-08-19 |
2018-11-07 |
Pfizer |
Inhibidores de diacilglicerol aciltransferasa 2
|
|
JP2020500838A
(ja)
|
2016-10-14 |
2020-01-16 |
ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ |
Α−アミノ−β−カルボキシムコン酸セミアルデヒドデカルボキシラーゼの阻害剤
|
|
WO2018106518A1
(en)
|
2016-12-06 |
2018-06-14 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
|
WO2018118670A1
(en)
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
|
WO2020044266A1
(en)
|
2018-08-31 |
2020-03-05 |
Pfizer Inc. |
Combinations for treatment of nash/nafld and related diseases
|
|
KR20210111248A
(ko)
|
2018-11-20 |
2021-09-10 |
테스 파마 에스.알.엘. |
α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제
|
|
CA3140972C
(en)
|
2019-05-20 |
2024-06-18 |
Pfizer Inc. |
Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
|
|
JP7467510B2
(ja)
*
|
2019-11-07 |
2024-04-15 |
エルジー・ケム・リミテッド |
メラノコルチン－４受容体アゴニスト
|
|
US20240059652A1
(en)
*
|
2020-12-22 |
2024-02-22 |
Lg Chem, Ltd. |
Amorphous melanocortin receptor agonist and method for preparing same
|
|
US20250066337A1
(en)
|
2021-08-26 |
2025-02-27 |
Pfizer Inc. |
Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide
|
|
WO2024118524A1
(en)
|
2022-11-28 |
2024-06-06 |
Cerevel Therapeutics, Llc |
Azaindole compounds and their use as phosphodiesterase inhibitors
|